Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 152-155

  Eap, C B ^a,c   Sirot, E Jaquenoud ^b   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b Psychiat Dienste des Kantons Aargau   (Switzerland)

^c Hopital de Cery   (Switzerland)

Author keywords

Compliance; Cytochrome P450; Pharmacogenetics; Pharmacogenomics; Therapeutic drug monitoring

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

BIOEQUIVALENCE; CONFERENCE PAPER; DIET; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MONITORING; GENOTYPE; HEREDITY; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; SMOKING;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; GENOTYPE; HUMANS; PATIENT COMPLIANCE; PHARMACOGENETICS;

EID: 16544371097     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00011     Document Type: Conference Paper

References (38)

1. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants-cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37:147-165.
2. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.
3. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
4. Aitman TJ. DNA microarrays in medical practice. Br Med J. 2001;323:611-615.
5. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342-349.
6. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med. 2003;81:154-167.
7. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193-202.
8. Bertilsson L, Dahl M-L, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand. 1997;96:14-21.
9. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19:23S-35S.
10. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors-an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32:1-21.
11. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996;60:512-521.
12. Dalen P, Dahl M-L, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63:444-452.
13. Baumann P, Eap CB. Pharmacogenetics of chiral psychotropic drugs. In: Lerer B, ed. Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press, 2002:181-214.
14. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9:55-60.
15. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol. 2001;21:330-334.
16. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-443.
17. Eap CB, Lessard E, Baumann P, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics. 2003;13:39-47.
18. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52:23-33.
19. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
20. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154.
21. Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry. 1997;58:31-36.
22. Myers ED, Branthwaite A. Outpatient compliance with antidepressant medication. Br J Psychiatry. 1992;160:83-86.
23. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol. 1994;8:48-53.
24. Thompson C, Peveler RC, Stephenson D, et al. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry. 2000;157:338-343.
25. Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
26. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573-585.
27. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387-398.
28. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;11:447-458.
29. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48-56.
30. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268-273.
31. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825-831.
32. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, et al. Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP. Mutat Res. 2002;500:103-110.
33. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229.
34. Westlind A, Lofberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun. 1999;259:201-205.
35. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
36. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 2001;27:383-391.
37. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779.
38. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′ -hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 2002;30:1491-1496.